Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Teva Pharmaceutical Industries Ltd (TEVA) Earnings: An Early Look

Page 1 of 2

Earnings season is in full swing, with huge numbers of companies having already given their latest numbers to investors. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)Let’s turn to Teva Pharmaceutical Industries Ltd (NYSE:TEVA) . The drug company has a unique balance, profiting from generics on one hand yet having its own proprietary drugs on the other. Let’s take an early look at what’s been happening with Teva Pharmaceutical over the past quarter and what we’re likely to see in its quarterly report on Thursday.

Stats on Teva Pharmaceutical

Analyst EPS Estimate $1.33
Change from Year-Ago EPS (16%)
Revenue Estimate $5.26 billion
Change from Year-Ago Revenue (7.4%)
Earnings Beats in Past 4 Quarters 3

Source: Yahoo! Finance.

Will Teva Pharmaceutical stay healthy?
Analysts have been pretty certain about their estimates for Teva Pharmaceutical in the just-concluded quarter, but over the past three months, they’ve pulled in their estimates for the first quarter and full-year 2013 sharply. The stock has been equally pessimistic, falling almost 8% since early November.

Teva is best known for its generic versions of off-patent drugs. Given how much less expensive generic versions are compared to their branded equivalents, health-care advocates argue that they’re essential to keeping drug costs down, even though they also discourage innovation. Teva hasn’t been content to stick with generics solely, though, also working on branded drugs. Its blockbuster drug is Copaxone, which is a treatment for multiple sclerosis.

For Copaxone, though, competition is on the horizon. Teva filed what’s known as a citizen’s petition with the FDA to try to delay approval of Biogen Idec Inc. (NASDAQ:BIIB)‘s BG-12 treatment for MS, which will go up directly against Copaxone if approved.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!